Amgen Inc (AMGN) has been the focal point in the biotech market with ups and downs recently. Its Q4 results outperformed estimates, achieving an extra $400 million causing analysts to predict a $350 target. Several wealth management firms are augmenting their holdings whereas, some firms are decreasing theirs. The strong financial performance has led some to consider AMGN as a secure value stock. However, the possibility of liver injury risks from their rare disease drug Tavneos resulted in FDA warnings, causing minor stock falls. Concurrently, collaborations with Zai Lab and the study of lung cancer combination therapy hold promise towards infusing new vigor into the stock. The narrative is being reshaped with optimism about MariTide and exclusivity discussions. Analysts have adjusted price targets accordingly. Despite the varied effects, the market value improved with AMGN shares showing sustained momentum. The possibility of a significant increase in free cash flow by 2026 and a focus on obesity drugs could be a game-changer. However, serious liver risks associated with Tavneos balances the optimism. Yet, based on current trends, the question whether AMGN is a valuable long-term investment is yet to be determined.
Amgen AMGN News Analytics from Tue, 09 Dec 2025 08:00:00 GMT to Sat, 04 Apr 2026 10:34:03 GMT -
Rating 2
- Innovation 5
- Information 7
- Rumor -5
